We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > antisense oligonucleotide

News List

Chinese Produced ASO Drug Innovation Therapy for Functional Cure of Chronic Hepatitis B Has Obtained FDA Clinical Approval Xiaoyaowan/Pharmasources
September 08, 2023
Recently, Haobo Pharmaceuticals announced that their investigational antisense oligonucleotide (ASO) drug AHB-137 has received clinical trial approval from the FDA in the United States for use in patients with chronic hepatitis B.
Empirico, Ionis collaborate to develop antisense oligonucleotide therapeutics pharmaceutical-business-review
January 14, 2020
Empirico has entered into a $660m deal with Ionis Pharmaceuticals to develop novel antisense oligonucleotide therapeutics. Under the three-year collaboration, Empirico will use its Precision Insights Platform to determine therapeutic targets for indicatio
NICE recommends Akcea's Tegsedi for rare, life-threatening progressive disease pharmafile
April 23, 2019
NICE recommends Akcea's Tegsedi for rare, life-threatening progressive disease